

Press Release

Granules India's Net Profit for first quarter of Financial Year 2020 increases by 61%

Hyderabad, 30th July 2019: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today its result for its first quarter of financial year 2020.

CONSOLIDATED FINANCIALS	Q1FY'20	Q1FY'19	Growth (Y-o-Y)
Income from Operation	INR 595 Crs.	INR 453 Crs.	31%
Operating Profit	INR 119 Crs.	INR 73 Crs.	63%
Operating Profit Margin	19.9 %	16.0 %	
Net Profit	INR 83 Crs.	INR 52 Crs.	61%
Net Profit Margin	13.9 %	11.1 %	

STANDALONE FINANCIALS	Q1FY'20	Q1FY'19	Growth (Y-o-Y)
Income from Operation	INR 568 Crs.	INR 440 Crs.	29%
Operating Profit	INR 119 Crs.	INR 70 Crs.	70%
Operating Profit Margin	20.9 %	15.8 %	
Net Profit	INR 60 Crs.	INR 40 Crs.	50%
Net Profit Margin	10.5 %	8.6 %	

The Company's Board of Directors has approved first interim dividend of 25 paise per share of face value of Re. 1 each.

"We continue our growth momentum with the first quarter of FY20 showing encouraging results. Our total Revenue from operations increased by 31% and net profit by 61% compared to the same period of previous year. The sustained growth in our high volume based molecules business and our unwavering focus on US market enabled us to achieve the growth. One of the key pillars of our business model has been driving operational efficiencies and along with it a better product mix helped us improve the Operating and Net profit margins in this quarter. During the quarter we have filed 3 ANDAs and received approval for 2 ANDAs from US FDA filed earlier. In continuation to our commitment to improve the leverage position of the Company, this quarter has also witnessed improvement in our net debt position." said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited.



About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K. The Company has 8 manufacturing facilities out of which 6 are located in India, 1 in China and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Contacts:

Sumanta Bajpayee
Head - Corporate Finance, Treasury & Investor Relations
040-30663572
sumanta.bajpayee@granulesindia.com

Chaitanya Tummala
Company Secretary
040-30663614
chaitanya.tummala@granulesindia.com

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.